NL0000009538 - Common Stock

Taking everything into account, **PHIA** scores **4** out of 10 in our fundamental rating. **PHIA** was compared to 55 industry peers in the **Health Care Equipment & Supplies** industry. **PHIA** has a bad profitability rating. Also its financial health evaluation is rather negative. **PHIA** is not valued too expensively and it also shows a decent growth rate.

In multiple years **PHIA** reported negative net income over the last 5 years.

Of the past 5 years **PHIA** 4 years had a positive operating cash flow.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -1.58% | ||

ROE | -3.87% | ||

ROIC | N/A |

ROA(3y)1.3%

ROA(5y)2.5%

ROE(3y)2.33%

ROE(5y)5.25%

ROIC(3y)N/A

ROIC(5y)N/A

In the last couple of years the **Operating Margin** of **PHIA** has declined.

The **Gross Margin** of **PHIA** (**41.00%**) is worse than **67.92%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 41% |

OM growth 3Y-40.52%

OM growth 5Y-26.4%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.47%

GM growth 5Y-1.32%

The number of shares outstanding for **PHIA** has been reduced compared to 1 year ago.

Compared to 5 years ago, **PHIA** has more shares outstanding

Based on the Altman-Z score of **1.79**, we must say that **PHIA** is in the distress zone and has some risk of bankruptcy.

The Debt to FCF ratio of **PHIA** is **4.76**, which is a neutral value as it means it would take **PHIA**, **4.76** years of fcf income to pay off all of its debts.

A Debt/Equity ratio of **0.58** indicates that **PHIA** is somewhat dependend on debt financing.

With a **Debt to Equity ratio** value of **0.58**, **PHIA** is not doing good in the industry: **62.26%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.58 | ||

Debt/FCF | 4.76 | ||

Altman-Z | 1.79 |

ROIC/WACCN/A

WACC6.47%

Looking at the **Current ratio**, with a value of **1.20**, **PHIA** is doing worse than **69.81%** of the companies in the same industry.

With a **Quick ratio** value of **0.78**, **PHIA** is not doing good in the industry: **67.92%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.2 | ||

Quick Ratio | 0.78 |

Looking at the last year, **PHIA** shows a small growth in **Revenue**. The Revenue has grown by **1.92%** in the last year.

EPS 1Y (TTM)11.66%

EPS 3Y-15.7%

EPS 5Y-2.67%

EPS Q2Q%5.46%

Revenue 1Y (TTM)1.92%

Revenue growth 3Y1.62%

Revenue growth 5Y0.05%

Sales Q2Q%-0.85%

Based on estimates for the next years, **PHIA** will show a small growth in **Revenue**. The Revenue will grow by **4.56%** on average per year.

EPS Next Y19.07%

EPS Next 2Y13.84%

EPS Next 3Y14.36%

EPS Next 5Y16.13%

Revenue Next Year1.13%

Revenue Next 2Y3.01%

Revenue Next 3Y3.58%

Revenue Next 5Y4.56%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

A **Price/Earnings** ratio of **20.23** indicates a rather expensive valuation of **PHIA**.

Based on the **Price/Earnings** ratio, **PHIA** is valued a bit cheaper than 79.25% of the companies in the same industry.

Based on the **Price/Forward Earnings** ratio, **PHIA** is valued a bit cheaper than the industry average as 73.58% of the companies are valued more expensively.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **20.38**, **PHIA** is valued at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 20.23 | ||

Fwd PE | 16.37 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **PHIA** is on the same level as its industry peers.

Based on the **Price/Free Cash Flow** ratio, **PHIA** is valued cheaper than 96.23% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 15.21 | ||

EV/EBITDA | 26.59 |

The **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

PEG (NY)1.06

PEG (5Y)N/A

EPS Next 2Y13.84%

EPS Next 3Y14.36%

With a **Yearly Dividend Yield** of **4.15%**, **PHIA** is a good candidate for dividend investing.

Compared to an average industry **Dividend Yield** of **2.40**, **PHIA** pays a better dividend. On top of this **PHIA** pays more dividend than 98.11% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.15% |

The dividend of **PHIA** decreases each year by **-65.46%**.

Dividend Growth(5Y)-65.46%

Div Incr Years0

Div Non Decr Years0

The earnings of **PHIA** are negative and hence is the payout ratio. **PHIA** will probably not be able to sustain this dividend level.

DP-0.43%

EPS Next 2Y13.84%

EPS Next 3Y14.36%

**KONINKLIJKE PHILIPS NV**

AMS:PHIA (8/9/2024, 7:00:00 PM)

**26.3**

**-0.35 (-1.31%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap24.57B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.15% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 20.23 | ||

Fwd PE | 16.37 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.06

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -1.58% | ||

ROE | -3.87% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 41% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.62

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.58 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.2 | ||

Quick Ratio | 0.78 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)11.66%

EPS 3Y-15.7%

EPS 5Y

EPS Q2Q%

EPS Next Y19.07%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)1.92%

Revenue growth 3Y1.62%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y